The USPTO has reissued Pfizer's (PFE +1.5%) Celebrex patent, granting it exclusivity to December...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

The USPTO has reissued Pfizer's (PFE +1.5%) Celebrex patent, granting it exclusivity to December 2015. The decision gives the drug giant U.S. exclusivity - and a monopoly sales - for an additional 18 months. The reissued patent covers methods of treating osteoarthritis and other approved conditions with celecoxib, the active ingredient in Celebrex, whose prior patent was previously invalidated by a federal appeals court in 2008.